Click to Share
 
 
  1. Latest News
  2. Submit Press Release

antibody Press Releases

  + XML/RSS  



By Cambridge Healthtech Institute
Bringing Industry, Academia and Regulatory Authorities Together to Produce Safe and Efficacious Products for the Clinic and Beyond
By Cambridge Healthtech Institute
Delegates now have the option to choose from 9 moderated breakout discussion groups on immunogenicity facilitated by industry and academic experts.
By ImmunoChemistry Technologies
Conjugate stabilizers prolong the shelf-life of conjugated antibodies and other proteins, enhancing their utility in ELISA and Western applications.
By Cambridge Healthtech Institute
Over 1,600 scientists will convene at this annual event to celebrate the evolution of biologics, and the generation, characterization, and clinical application of proteins.
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.
By Visiongain
A new report by Visiongain shows that next-generation technologies will become a major driver for the antibody therapeutics market.
By Cambridge Healthtech Institute
CHI’s 4th Annual Cancer Biologics, February 13-15, 2013, San Francisco, CA
By Sedia Biosciences Corp.
Phase I funding of the competitive grant is to develop a novel commercial assay to measure host HIV antibody avidity ("binding ability"), an indicator of antibody maturation, which can be used to determine recent vs. long-term HIV-1 infections.
By tebu-bio
tebu-bio is proud to announce that they have been awarded the designation of Certified Service Provider (CSP) of RayBiotech’s antibody array testing services.
By China Research and Intelligence
Monoclonal antibody still belongs to high-end products in Chinese market, mainly depending on imports.
By Adrienne O'Reilly
New pre-clinical and clinical data on Mentrik Biotech’s ocaratuzumab, a humanized, next-generation anti-CD20 monoclonal antibody for treatment of follicular lymphoma, was released in Clinical Cancer Research, published by the AACR.
By GTC Conference
David Woodward, Senior Director of Biological Sciences at Allergan and Barbara Wirostko, Chief Medical Officer at Altheos will give a joint featured presentation at the 4th Ocular Diseases and Drug Discovery Conference

All Press Releases

By GeneTex
GeneTex offers an outstanding selection of antibodies to support hypoxia research.
By Visiongain
A new report by visiongain predicts that the world next-generation antibody therapies market will reach $2.3bn in 2015.
By GeneTex
GeneTex proudly offers a large selection of high-quality antibodies for cancer research, including well-validated TSG101 antibodies.
By GeneTex
GeneTex proudly offers a large selection of high-quality antibodies for stem cell and neuroscience research, including well-validated Vimentin antibodies.
By GeneTex
GeneTex is very proud to offer an outstanding mouse monoclonal antibody that detects γ-H2AX.
By GeneTex
GeneTex proudly offers a large selection of high-quality antibodies for stem cell and cancer research, including well-validated CD44 antibodies.
By GeneTex
GeneTex proudly offers a large selection of high-quality antibodies for stem cell research, including well-validated CD45 antibodies.
By GeneTex
Ki-67 is a nonhistone nuclear protein that is detectable in all active stages of the cell cycle, but not in resting cells.
By GeneTex
GeneTex is proud to offer an excellent selection of Oct4 and related antibodies to assist in your research!
By GeneTex
Colorectal cancer is the second leading cause of cancer-related death in the United States.
By GeneTex
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer among men and continues to pose a major clinical challenge for diagnosis and treatment.
By GeneTex
GeneTex proudly offers excellent Notch1 antibodies to assist your neural systems research.
By GeneTex
GeneTex proudly offers an excellent selection of SOX2 and related antibodies to assist your embryonic stem cell research.
By GeneTex
Immunotherapeutic approaches to cancer treatment continue to generate great interest.
By GeneTex
GeneTex proudly offers an excellent selection of FIS1 and related antibodies to assist your mitochondrial research.
By GeneTex
GeneTex proudly offers excellent doublecortin antibodies to assist in your neuroscience research.
By GeneTex
GeneTex proudly offers an excellent Nanog antibody to assist your embryonic stem cell research.
By GeneTex
Push your research forward with Nestin! GeneTex proudly offers an excellent Nestin antibody to assist your neural systems research.
By GeneTex
Don’t run out of Runx2 antibody! GeneTex's Runx2 is well validated and ready to help accelerate your research!
By GeneTex
Cas9 antibody for ICC/IF, IP, WB - Mouse monoclonal antibody [7A9] to Cas9
By ImmunoReagents Inc.
RALEIGH, NC, USA – May 19, 2015 – U.S. Secretary of Commerce Penny Pritzker has presented ImmunoReagents with the President’s “E” Award for Exports at a ceremony in Washington, DC.
By GeneTex
TET1 antibody for ICC/IF, IHC, IHC-P, WB and ChIP Assay. N3C1 polyclonal.
By GeneTex
Immunotherapeutic approaches to cancer treatment continue to generate great interest. In an excellent Nature Reviews Cancer "Perspectives" discussion, Coulie et.al.
By SMi Group Ltd
SMi’s 4th annual ADC Summit 2015, taking place on the 18th - 19th May 2015, will be held at Holiday Inn Bloomsbury in London, UK.
By Cambridge Healthtech Institute
Bringing Industry, Academia and Regulatory Authorities Together to Produce Safe and Efficacious Products for the Clinic and Beyond
By Cambridge Healthtech Institute
Delegates now have the option to choose from 9 moderated breakout discussion groups on immunogenicity facilitated by industry and academic experts.
By ImmunoChemistry Technologies
Conjugate stabilizers prolong the shelf-life of conjugated antibodies and other proteins, enhancing their utility in ELISA and Western applications.
By Cambridge Healthtech Institute
Over 1,600 scientists will convene at this annual event to celebrate the evolution of biologics, and the generation, characterization, and clinical application of proteins.
By smi group
SMi's Antibody Drug Conjugate masterclass, taking place on the 2 December in London, will provide comprehensive insights into CMC issues during the development, with a particular focus on the assessment and control of the quality of such products.
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.
By Biotech Support Group
NuGel™ Poly-Amine for affinity purification of interleukin enhancer binding factor 3 (Ilf3) and nuclear factor 90 (NF90) interactome
By Visiongain
A new report by Visiongain shows that next-generation technologies will become a major driver for the antibody therapeutics market.
By Cambridge Healthtech Institute
CHI’s 4th Annual Cancer Biologics, February 13-15, 2013, San Francisco, CA
By Insight Pharma Reports
The New Generation of Antibody Therapeutics: Current Status and Future Prospects
By Sedia Biosciences Corp.
Phase I funding of the competitive grant is to develop a novel commercial assay to measure host HIV antibody avidity ("binding ability"), an indicator of antibody maturation, which can be used to determine recent vs. long-term HIV-1 infections.
By tebu-bio
tebu-bio is proud to announce that they have been awarded the designation of Certified Service Provider (CSP) of RayBiotech’s antibody array testing services.
By China Research and Intelligence
Monoclonal antibody still belongs to high-end products in Chinese market, mainly depending on imports.
By Cambridge Healthtech Institute
Those that missed last month's event can get a CD with 80 speaker presentations from 4 pipelines: formulation, purification, biotherapeutics, and expression. Individual track CDs and the overall event CD is available at CHI-PepTalk.com.
By Adrienne O'Reilly
New pre-clinical and clinical data on Mentrik Biotech’s ocaratuzumab, a humanized, next-generation anti-CD20 monoclonal antibody for treatment of follicular lymphoma, was released in Clinical Cancer Research, published by the AACR.
By GTC Conference
David Woodward, Senior Director of Biological Sciences at Allergan and Barbara Wirostko, Chief Medical Officer at Altheos will give a joint featured presentation at the 4th Ocular Diseases and Drug Discovery Conference
By Visiongain
A new report by Visiongain predicts that overall revenues for monoclonal antibody (mAb) therapies will rise between 2011 and 2021. The world mAb drugs market will reach $62.3bn in 2015, up from revenues of $44.6bn (USD) in 2010.
By Insight Pharma Reports
Engineering Next-Generation Therapeutic Proteins: Trends and Markets To 2020 Report
By AbboMax, Inc
Desmogleins are members of the desmosomal cadherins that provide adhesive integrity to desmosomes between adjoining keratinocytes. Desmoglein 3 is autoantigen of the autoimmune disease pemphigus vulgaris, and plays role in squamous cell cancer.
By AnaSpec EGT Group
Leveraging proven technology from Eurogentec, AnaSpec's parent company, this protocol uses a proprietary mixture of Freund's free immuno-stimulatory compounds.
By AnaSpec
AnaSpec, Eurogentec Group is pleased to offer anti-5-methylcytidine (Clone 33D3), Eurogentec’s most popular monoclonal antibody, for use in epigenetics research.
By RayBiotech, Inc.
RayBiotech, Inc., announced today it will renew its Biomarker Discovery Pilot Grant program for 2011 and will accept applications for restricted pilot grants of $5,000 to $20,000 worth of RayBiotech products and/or services beginning in early 2011.
By Sara Pierre
Since the launch of their first mini-website dedicated to SilenciX, tebu-bio has subsequently released sites focussed on Preadipocytes and Antibody Arrays, with the most recent addition now centered around CryostaX™.
By OBodies Limited
Therapeutic protein and antibody engineering expert Dr. Mark Liddament appointed Research Manager at OBodies
By Bharatbook
Bharatbook added a new report on "Antibody Technology Companies 2010" into its market report catalogue for reselling.
By ReportBuyer.com
According to our new research report 'Global Monoclonal Antibody Market Analysis', the global monoclonal antibodies market witnessed an annual growth rate of around 13% during 2008-2009.


Page:

Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share